{
    "questions": [
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36113495"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "INTERPRETATION: Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and CGRP probably does not have an important role in paroxysmal pain.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113495",
                    "offsetInBeginSection": 2839,
                    "offsetInEndSection": 3023
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "There was no difference between groups in the number of responders at 4 weeks in the intention-to-treat population (14 [35%] of 40 with erenumab vs 18 [45%] of 40 with placebo; estimated effect size -10% [95% CI -31 to 11]; p=0\u00b736). 20 (50%) of 40 participants reported adverse events in each group. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113495",
                    "offsetInBeginSection": 2356,
                    "offsetInEndSection": 2656
                }
            ],
            "id": "63f73f1b33942b094c000008",
            "type": "yesno",
            "body": "Is erenumab effective for trigeminal neuralgia?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34304240",
                "http://www.ncbi.nlm.nih.gov/pubmed/34774197"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine raises no safety concerns and preserves antibody responses to both vaccines. Concomitant vaccination with both COVID-19 and influenza vaccines over the next immunisation season should reduce the burden on health-care services for vaccine delivery, allowing for timely vaccine administration and protection from COVID-19 and influenza for those in need.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34774197",
                    "offsetInBeginSection": 3147,
                    "offsetInEndSection": 3590
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "It is unknown if the efficacy of the coronavirus disease-19 (COVID-19) vaccine is affected by the co-administration of other vaccines. The Centers for Disease Control and Prevention (CDC) has shifted their recommendations recently, allowing for the co-administration of the currently available COVID-19 vaccines with other vaccines. This is based on the experience with non-COVID-19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34304240",
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 535
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Although the administration of Tdap with COVID-19 vaccine in our case caused delay in immunogenicity, it did not negate the ability of the BNT162B2 mRNA vaccine to elicit an adequate immune response.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34304240",
                    "offsetInBeginSection": 1188,
                    "offsetInEndSection": 1387
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34774197",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 243
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34774197",
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 571
                }
            ],
            "id": "643c88a257b1c7a315000030",
            "type": "yesno",
            "body": "Can other vaccines be given with COVID-19 vaccine?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34919292",
                "http://www.ncbi.nlm.nih.gov/pubmed/31532835",
                "http://www.ncbi.nlm.nih.gov/pubmed/25467598"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This review supports the beneficial effects of music-based interventions on the health of preterm infants in a neonatal intensive care unit; however, it also offers suggestions for future studies in order to increase the number of interventions with music therapists, since the results of music therapy approaches were more consistent for physiological and behavioural outcomes.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34919292",
                    "offsetInBeginSection": 950,
                    "offsetInEndSection": 1328
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "No effect of a musical intervention on stress response to venepuncture in a neonatal population.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31532835",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Our findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31532835",
                    "offsetInBeginSection": 1359,
                    "offsetInEndSection": 1496
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "BF could significantly reduce pain response in healthy-term neonates during heel lance. MT did not enhance the effect of pain relief of BF.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467598",
                    "offsetInBeginSection": 1547,
                    "offsetInEndSection": 1686
                }
            ],
            "id": "6441302d57b1c7a315000056",
            "type": "yesno",
            "body": "Is music therapy effective for pain management in neonates?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33660024",
                "http://www.ncbi.nlm.nih.gov/pubmed/33603399",
                "http://www.ncbi.nlm.nih.gov/pubmed/33074559",
                "http://www.ncbi.nlm.nih.gov/pubmed/33344554",
                "http://www.ncbi.nlm.nih.gov/pubmed/30736994"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "ACANTHOSIS NIGRICANS MALIGNA: Symmetrical mainly intertriginous hyperpigmentation with partially verrucous hyperplasia and lichenification mostly in association with gastric adenocarcinoma. Special forms are florid cutaneous papillomatosis and tripe palms.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33660024",
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 720
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Bladder cancer with AN concomitant with tripe palms (TP) and/or mucosal involvement is relatively rare and, to our knowledge, only seven cases of AN with bladder cancer have been reported in the English literature. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33603399",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 720
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "BACKGROUND: Tripe palms (TP) is one of the rare cutaneous paraneoplastic manifestations of various intra-abdominal malignancies. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33074559",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "BACKGROUND: Acanthosis nigricans (AN), Leser-Tr\u00e9lat sign, and tripe palm are all skin diseases. To date, reports of these appearing as a paraneoplastic syndrome in a gastric cancer patient are quite rare.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33344554",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Finally, yet another collection of paraneoplastic skin disorders can associate themselves with anatomically-diverse malignancies (Leser-Trelat syndrome, Trousseau syndrome, dermatomyositis, erythema gyratum repens, hypertrichosis lanuginosa acquisita, papuloerythroderma of Ofuji, tripe palms, and multicentric reticulohistiocytosis). Recognition of these processes by the pathologist can be a valuable step in the characterization of underlying malignant diseases.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30736994",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1501
                }
            ],
            "id": "63f02b50f36125a426000014",
            "type": "yesno",
            "body": "Is there any association between Tripe palms and cancer?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15189359",
                "http://www.ncbi.nlm.nih.gov/pubmed/30509290"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are caused by mutations in the super oxide dismutase 1 (SOD1) gene a",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15189359",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": ". The two most widely studied ALS/FTLD models, super-oxide dismutase 1 (SOD1)",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30509290",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 795
                }
            ],
            "id": "641c516d690f196b5100003f",
            "type": "yesno",
            "body": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35181864",
                "http://www.ncbi.nlm.nih.gov/pubmed/34318930",
                "http://www.ncbi.nlm.nih.gov/pubmed/36411267",
                "http://www.ncbi.nlm.nih.gov/pubmed/36399336",
                "http://www.ncbi.nlm.nih.gov/pubmed/33284679",
                "http://www.ncbi.nlm.nih.gov/pubmed/34669839",
                "http://www.ncbi.nlm.nih.gov/pubmed/34153975"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Casirivimab/imdevimab (REGN-COV), a cocktail of neutralizing antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, was shown to be an effective treatment and post-exposure prophylaxis measure for coronavirus disease 2019 (COVID-19).",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35181864",
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 317
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The high titer of IgGSP supports the clinical benefit of therapeutic and prophylactic use of REGN-COV from the serological point of view.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35181864",
                    "offsetInBeginSection": 1248,
                    "offsetInEndSection": 1385
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "We collected serological data of patients with COVID-19 who were treated with REGN-COV 1200\u00a0mg (casirivimab 600\u00a0mg/imdevimab 600\u00a0mg).",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35181864",
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 636
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Based on the current very low- to low-certainty evidence, we are uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID-19. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34318930",
                    "offsetInBeginSection": 6283,
                    "offsetInEndSection": 6437
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Overall, the reliable evidence available does not support the use ivermectin for treatment or prevention of COVID-19 outside of well-designed randomized trials.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34318930",
                    "offsetInBeginSection": 6587,
                    "offsetInEndSection": 6747
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Currently, evidence on efficacy and safety of ivermectin for prevention of SARS-CoV-2 infection and COVID-19 treatment is conflicting.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34318930",
                    "offsetInBeginSection": 337,
                    "offsetInEndSection": 471
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "We report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19).",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411267",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 182
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This study did not meet the primary efficacy endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 versus placebo.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411267",
                    "offsetInBeginSection": 1503,
                    "offsetInEndSection": 1637
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This systematic review was performed to determine the population that benefited from prophylactic ivermectin. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36399336",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Ivermectin was associated with a lower risk of COVID-19 (OR, 0.22; 95% CI, 0.12-0.40) in the pre-exposure population, whereas no protective effect was observed in the post-exposure population (OR, 0.39; 95% CI, 0.09-1.67). In summary, prophylactic ivermectin did not prevent COVID-19 in the post-exposure population. Although the protective effect of ivermectin was shown in the overall and pre-exposure populations, the results were unreliable owing to poor-quality evidence.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36399336",
                    "offsetInBeginSection": 968,
                    "offsetInEndSection": 1444
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33284679",
                    "offsetInBeginSection": 2052,
                    "offsetInEndSection": 2251
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33284679",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 203
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "To test hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33284679",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 453
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Chloroquine or hydroxychloroquine has demonstrated no effect on the treatment of hospitalized COVID-19 patients. This study aimed to answer questions related to the use of hydroxychloroquine for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection and in the treatment of patients with mild COVID-19 in terms of hospitalization, adverse events, and mortality.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669839",
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 383
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection or treatment of patients with mild COVID-19 is not recommended.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669839",
                    "offsetInBeginSection": 1382,
                    "offsetInEndSection": 1515
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "No statistically significant differences were found between the hydroxychloroquine and control groups in terms of pre- or post-exposure prophylaxis of SARS-CoV-2 infection.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669839",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 946
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures. Although cell culture experiments have demonstrated a loss of potency of several anti-spike neutralizing antibodies against variant strains of SARS-CoV-21-3, the in vivo importance of these results remains uncertain.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34153975",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Therefore, many-but not all-of the antibody products with Emergency Use Authorization should retain substantial efficacy against the prevailing variant strains of SARS-CoV-2.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34153975",
                    "offsetInBeginSection": 1302,
                    "offsetInEndSection": 1476
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Although some individual mAbs showed reduced or abrogated neutralizing activity in cell culture against B.1.351, B.1.1.28, B.1.617.1 and B.1.526 viruses with mutations at residue E484 of the spike protein, low prophylactic doses of mAb combinations protected against infection by many variants in K18-hACE2 transgenic mice, 129S2 immunocompetent mice and hamsters, without the emergence of resistance. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34153975",
                    "offsetInBeginSection": 548,
                    "offsetInEndSection": 950
                }
            ],
            "id": "643c396457b1c7a31500002d",
            "type": "yesno",
            "body": "Are any medications available to prevent COVID-19 following exposure?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33971103"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33971103",
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 959
                }
            ],
            "id": "6440092d57b1c7a315000040",
            "type": "yesno",
            "body": "Has RTA 408 received FDA approval?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35904405",
                "http://www.ncbi.nlm.nih.gov/pubmed/34043841",
                "http://www.ncbi.nlm.nih.gov/pubmed/35593164",
                "http://www.ncbi.nlm.nih.gov/pubmed/35233580",
                "http://www.ncbi.nlm.nih.gov/pubmed/36298593",
                "http://www.ncbi.nlm.nih.gov/pubmed/36275814",
                "http://www.ncbi.nlm.nih.gov/pubmed/34459525"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "A precise estimate of the frequency and severity of SARS-CoV-2 reinfections would be critical to optimize restriction and vaccination policies for the hundreds of millions previously infected subjects. We performed a meta-analysis to evaluate the risk of reinfection and COVID-19 following primary infection.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904405",
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 322
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Reinfection rates were still 0.66% after \u226512\u2009months from first infection, and the risk was substantially lower among vaccinated subjects (0.32% vs. 0.74% for unvaccinated individuals). During the first 3\u00a0months of Omicron wave, the reinfection rates reached 3.31%.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904405",
                    "offsetInBeginSection": 921,
                    "offsetInEndSection": 1185
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "A strong natural immunity follows the primary infection and may last for more than one year, suggesting that the risk and health care needs of recovered subjects might be limited. Although the reinfection rates considerably increased during the Omicron wave, the risk of a secondary severe or lethal disease remained very low.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904405",
                    "offsetInBeginSection": 1357,
                    "offsetInEndSection": 1683
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Despite over 140\u00a0million SARS-CoV-2 infections worldwide since the beginning of the pandemic, relatively few confirmed cases of SARS-CoV-2 reinfection have been reported. While immunity from SARS-CoV-2 infection is probable, at least in the short term, few studies have quantified the reinfection risk.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34043841",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 302
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Reinfection was an uncommon event (absolute rate 0%-1.1%), with no study reporting an increase in the risk of reinfection over time. Only one study estimated the population-level risk of reinfection based on whole genome sequencing in a subset of patients; the estimated risk was low (0.1% [95% CI: 0.08-0.11%]) with no evidence of waning immunity for up to 7\u00a0months following primary infection. These data suggest that naturally acquired SARS-CoV-2 immunity does not wane for at least 10\u00a0months post-infection. However, the applicability of these studies to new variants or to vaccine-induced immunity remains uncertain.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34043841",
                    "offsetInBeginSection": 1006,
                    "offsetInEndSection": 1627
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The risk of reinfection increased almost 18-fold following emergence of the Omicron variant compared with Delta.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35593164",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 339
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection is needed.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 120
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This large US population-based study demonstrates that SARS-CoV-2 reinfection is uncommon among individuals with laboratory evidence of a previous infection. Protection from SARS-CoV-2 reinfection is stable up to one year.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580",
                    "offsetInBeginSection": 2153,
                    "offsetInEndSection": 2375
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580",
                    "offsetInBeginSection": 1807,
                    "offsetInEndSection": 1926
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Among >22 million individuals tested February 2020 through April 2021, the relative risk of reinfection among those with prior infection was 87% lower than the risk of infection among individuals without prior infection. This protection was durable for up to a year.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580",
                    "offsetInBeginSection": 2800,
                    "offsetInEndSection": 3066
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36298593",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 695
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "SARS-CoV-2 infection does not confer long immunity. However, studies suggest that prior infection is associated with lower risk of reinfection and milder outcomes of recurrent infections.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36275814",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 199
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Reinfection with the SARS-CoV-2 Delta variant resulted in fewer hospitalizations compared to the primary Delta infection, suggesting that primary infection may, to some extent, produce at least short lasting protective immunity.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36275814",
                    "offsetInBeginSection": 2115,
                    "offsetInEndSection": 2343
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The vast majority of anti-spike IgG positive individuals remain anti-spike IgG positive for at least 8 months regardless of initial COVID-19 disease severity. The presence of anti-spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID-19.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459525",
                    "offsetInBeginSection": 1386,
                    "offsetInEndSection": 1705
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459525",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 266
                }
            ],
            "id": "643c446357b1c7a31500002f",
            "type": "yesno",
            "body": "Can reinfection occur after SARS-CoV-2 infection?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35729475",
                "http://www.ncbi.nlm.nih.gov/pubmed/35801871",
                "http://www.ncbi.nlm.nih.gov/pubmed/35773051",
                "http://www.ncbi.nlm.nih.gov/pubmed/36385359"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "RESULTS: Seven infants were diagnosed with SCID, yielding an incidence of 1 in 22,819 live births. Four of these infants had Artemis-type SCID.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35729475",
                    "offsetInBeginSection": 780,
                    "offsetInEndSection": 923
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Artemis deficiency disrupts development of adaptive immunity and leads to radiosensitive T- B- severe combined immunodeficiency (RS-SCID).",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35801871",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 426
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Encouraging data for X-SCID and preclinical work for Artemis-SCID and RAG1-SCID are paving the way for the therapy to become a viable curative treatment option.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35773051",
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 667
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Pathogenic variants in DCLRE1C encoding Artemis cause T-B-NK+ severe combined immunodeficiency (SCID), and patients with Artemis-deficient SCID (ART-SCID) require definitive therapy with allogeneic hematopoietic cell transplantation (HCT).",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36385359",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 350
                }
            ],
            "id": "63ee5eeaf36125a426000002",
            "type": "yesno",
            "body": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35322347",
                "http://www.ncbi.nlm.nih.gov/pubmed/8757902",
                "http://www.ncbi.nlm.nih.gov/pubmed/30646728",
                "http://www.ncbi.nlm.nih.gov/pubmed/23542331"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Wilson's disease (WD), an inherited disorder of copper metabolism that mostly affects the liver and brain;",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35322347",
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 261
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Wilsons disease is a rare autosomal recessive disorder of copper transportation, which is fatal if not treated.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8757902",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Wilsons disease and idiopathic toxicosis are examples of severe chronic liver diseases that are the results of genetic predisposition to the hepatic accumulation of copper.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30646728",
                    "offsetInBeginSection": 398,
                    "offsetInEndSection": 570
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Wilson disease is a genetic copper storage disorder that causes hepatic and neurologic symptoms. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542331",
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 116
                }
            ],
            "id": "640c821c201352f04a000023",
            "type": "yesno",
            "body": "Is Wilson's disease described as an iron storage disease?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 853
                }
            ],
            "id": "6440084357b1c7a31500003e",
            "type": "yesno",
            "body": "Is omaveloxolone an activator of NFkB?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35639288",
                "http://www.ncbi.nlm.nih.gov/pubmed/35179720",
                "http://www.ncbi.nlm.nih.gov/pubmed/34146511"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Efgartigimod is an FcRn inhibitor recently approved for MG treatment, and rozanolixizumab, nipocalimab and batoclimab are other agents in clinical trial development. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35639288",
                    "offsetInBeginSection": 1567,
                    "offsetInEndSection": 1733
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Efgartigimod (efgartigimod alfa-fcab, Vyvgart\u2122) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35179720",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 400
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35179720",
                    "offsetInBeginSection": 979,
                    "offsetInEndSection": 1118
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "INTERPRETATION: Efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34146511",
                    "offsetInBeginSection": 2951,
                    "offsetInEndSection": 3062
                }
            ],
            "id": "64040d73201352f04a000010",
            "type": "yesno",
            "body": "Can Efgartigimod be used for myasthenia gravis?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33709285"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Quercetin-biapigenin nanoparticles are effective to penetrate the blood-brain barrier.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33709285",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": " The present study aimed to investigate the potential protective effect of quercetin-biapigenin encapsulated into poly(\u0190-polycaprolactone) (PCL) nanoparticles against t-BOOH-induced oxidative stress in several brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro BBB model.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33709285",
                    "offsetInBeginSection": 436,
                    "offsetInEndSection": 757
                }
            ],
            "id": "6422e7ba690f196b51000044",
            "type": "yesno",
            "body": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36196023",
                "http://www.ncbi.nlm.nih.gov/pubmed/36314059",
                "http://www.ncbi.nlm.nih.gov/pubmed/34130310"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Epigenetic modifications have received increasing attention and have been shown to be extensively involved in kidney development and disease progression. Among them, the most common RNA modification, N6 -methyladenosine (m6 A), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mRNA fate.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36196023",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 405
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "N6-methyladenosine (m6A) methylation is the most abundant mammalian mRNA modification. m6A regulates RNA processing, splicing, nucleation, translation and stability by transferring, removing and recognizing m6A methylation sites, which are critical for cancer initiation, progression, metabolism and metastasis.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36314059",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 311
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The methyltransferase-like 3 (Mettl3) is a key component of the large N6-adenosine-methyltransferase complex in mammalian responsible for RNA N6-methyladenosine (m6A) modification, which plays an important role in gene post-transcription modulation.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34130310",
                    "offsetInBeginSection": 10,
                    "offsetInEndSection": 259
                }
            ],
            "id": "6429eb8457b1c7a31500000a",
            "type": "yesno",
            "body": "Is adenosine methylation an epigenetic modification?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36291504",
                "http://www.ncbi.nlm.nih.gov/pubmed/35620884",
                "http://www.ncbi.nlm.nih.gov/pubmed/34983147"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The duration between breastfeeding and heel lance may influence the perception of pain in newborns. Keeping this period short, may reduce the perception of pain.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983147",
                    "offsetInBeginSection": 1396,
                    "offsetInEndSection": 1557
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Breastfeeding and mother's heartbeat sounds, which are non-pharmacological pain relief methods, are effective in neonatal pain management. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35620884",
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1122
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "The best non-pharmacological methods are breastfeeding followed by non-nutritive sucking coupled with sucrose sucking. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504",
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1165
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": " Non-pharmacological interventions, particularly breastfeeding and non-nutritive sucking as primary strategies for pain management in neonates are useful strategies to consider.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504",
                    "offsetInBeginSection": 868,
                    "offsetInEndSection": 1045
                }
            ],
            "id": "64412c2757b1c7a315000055",
            "type": "yesno",
            "body": "Can breastfeeding be used to alleviate the procedural pain in neonates?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
                "http://www.ncbi.nlm.nih.gov/pubmed/36272024"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\u00a01 (HIV-1) being developed by Gilead Sciences Inc. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024",
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 554
                }
            ],
            "id": "64042000201352f04a000020",
            "type": "yesno",
            "body": "Can lenacapavir be used for HIV?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30738649",
                "http://www.ncbi.nlm.nih.gov/pubmed/31587658"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "INTERPRETATION: Prehospital treatment with transdermal GTN does not seem to improve functional outcome in patients with presumed stroke. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30738649",
                    "offsetInBeginSection": 2858,
                    "offsetInEndSection": 2995
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Conclusions- Prehospital treatment with GTN worsened outcomes in patients with intracerebral hemorrhage. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31587658",
                    "offsetInBeginSection": 1718,
                    "offsetInEndSection": 1823
                }
            ],
            "id": "6402c3fd201352f04a000009",
            "type": "yesno",
            "body": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 853
                }
            ],
            "id": "643ff48a57b1c7a31500003d",
            "type": "yesno",
            "body": "Is omaveloxolone a suppressor of Nrf2?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36282969"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "We observed the increase in SC concentrations in response to painful stimulus. The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective parameter to assess pain in neonates.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36282969",
                    "offsetInBeginSection": 1377,
                    "offsetInEndSection": 1604
                }
            ],
            "id": "64410f8057b1c7a315000054",
            "type": "yesno",
            "body": "Can salivary cortisol be used to evaluate pain in neonates?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35421369"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "INTERPRETATION: The addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle-invasive bladder cancer.FUNDING: Boehringer Ingelheim.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35421369",
                    "offsetInBeginSection": 2743,
                    "offsetInEndSection": 2938
                }
            ],
            "id": "6402c0d5201352f04a000008",
            "type": "yesno",
            "body": "Does nintedanib improve response rate in patients with bladder cancer?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31559909"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Neuronal-specific microexon splicing of TAF1 mRNA is directly regulated by SRRM4/nSR100.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Knockdown and ectopic expression experiments demonstrate that the neuronal-specific splicing factor SRRM4/nSR100 promotes the inclusion of microexon 34' into TAF1\u00a0mRNA, through the recognition of UGC sequences in the poly-pyrimidine tract upstream of the regulated microexon. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
                    "offsetInBeginSection": 688,
                    "offsetInEndSection": 964
                }
            ],
            "id": "63f9ee5c33942b094c000014",
            "type": "yesno",
            "body": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12181221",
                "http://www.ncbi.nlm.nih.gov/pubmed/11869491",
                "http://www.ncbi.nlm.nih.gov/pubmed/24972991"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "hey are genetically identical and those with twin-twin transfusion syndrome(TTTS) provide an ideal natural model in whom to study the influence of differing haemodynamic stresses on the developing vascular tre",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11869491",
                    "offsetInBeginSection": 341,
                    "offsetInEndSection": 550
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "n twin-to-twin transfusion syndrome (TTTS), genetically identical twins are exposed to different haemodynamic conditions during fetal life, which are considered to be the cause of prenatal and postnatal cardiovascular differences between the donor and the recipient",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24972991",
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 278
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": " To test the hypothesis that identical twins show no inter-twin differences in cardiovascular structure or physiology in fetal life unless there has been twin-twin transfusion syndrome.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12181221",
                    "offsetInBeginSection": 10,
                    "offsetInEndSection": 195
                }
            ],
            "id": "6431f71057b1c7a315000019",
            "type": "yesno",
            "body": "In twin-twin transfusion syndrome, are the twins identical?"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34429103",
                "http://www.ncbi.nlm.nih.gov/pubmed/35718324",
                "http://www.ncbi.nlm.nih.gov/pubmed/32543249",
                "http://www.ncbi.nlm.nih.gov/pubmed/26310015"
            ],
            "snippets": [
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Optogenetics allows the experimental manipulation of excitable cells by a light stimulus without the need for technically challenging and invasive procedures.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34429103",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 170
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Optogenetics has revolutionized the capability of controlling genetically modified neurons in\u00a0vitro and in\u00a0vivo and has become an indispensable neuroscience tool. Using light as a probe for selective neuronal activation or inhibition and as a means to read out neural activity has dramatically enhanced our understanding of complex neural circuits. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35718324",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 349
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "Optogenetics controls neural activity and behavior in living organisms through genetically targetable actuators and light. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32543249",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "This is a review of the current state of optogenetics-based research in the field of ophthalmology and physiology of vision. Optogenetics employs an interdisciplinary approach that amalgamates gene engineering, optics, and physiology. It involves exogenous expression of a light-activated protein in a very particular retinal cell enabling regulation (stimulation vs. inhibition) of its physiological activity",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26310015",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 409
                }
            ],
            "id": "6415b7b8690f196b5100000c",
            "type": "yesno",
            "body": "Optogenetics refers to the study of gene expression optimization"
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35767439",
                "http://www.ncbi.nlm.nih.gov/pubmed/29088386",
                "http://www.ncbi.nlm.nih.gov/pubmed/29594041",
                "http://www.ncbi.nlm.nih.gov/pubmed/24718705"
            ],
            "snippets": [
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35767439",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "METHODS: We conducted a single-center, dose-escalation study of DNX-2401, an oncolytic adenovirus that selectively replicates in tumor cells, in patients with newly diagnosed DIPG. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35767439",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 503
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "CONCLUSIONS: Intratumoral infusion of oncolytic virus DNX-2401 followed by radiotherapy in pediatric patients with DIPG resulted in changes in T-cell activity and a reduction in or stabilization of tumor size in some patients but was associated with adverse events.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35767439",
                    "offsetInBeginSection": 1971,
                    "offsetInEndSection": 2236
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088386",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "OBJECTIVE: To determine the safety, tolerability, and toxicity of an oncolytic adenovirus, DNX-2401, injected into the cerebellar peduncle in pediatric subjects with DIPG and to collect tumor samples of this type of tumor.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088386",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 641
                },
                {
                    "beginSection": "title",
                    "endSection": "title",
                    "text": "DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594041",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": "To this aim, we have designed a clinical Phase I trial for newly diagnosed pediatric DIPG to investigate the feasibility, safety, and preliminary efficacy of delivering DNX-2401 into tumors within the pons following biopsy.",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594041",
                    "offsetInBeginSection": 824,
                    "offsetInEndSection": 1047
                },
                {
                    "beginSection": "abstract",
                    "endSection": "abstract",
                    "text": " To our knowledge, this is the first report of intratumoral DNX-2401 for a patient with DIPG in a clinical trial. ",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594041",
                    "offsetInBeginSection": 1506,
                    "offsetInEndSection": 1620
                }
            ],
            "id": "63f03155f36125a426000019",
            "type": "yesno",
            "body": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?"
        }
    ]
}